<DOC>
	<DOCNO>NCT01297530</DOCNO>
	<brief_summary>This first study drug human being . Every patient receive drug , placebo group . Patients advance tumor treat . Different group patient receive different dosage determine safety maximum tolerate dose ( MTD ) BAY87-2243 . The study also assess drug metabolize body , biologic effect body , change tumor size . BAY87-2243 give tablet dissolve gut . Based finding study may later give tablet dissolve stomach . BAY87-2243 give per mouth , day , every day . Treatment stop tumor continue grow , side effect occur patient tolerate patient decide exit treatment . The study conduct 3 - 4 center 3 country ( Norway , United Kingdom Germany ) . The study part dose escalate different group patient . Each dose level evaluate new group 3 - 6 subject . This follow extension part patient treat high tolerable dose group 25 patient . The extension part describe amendment study protocol later . The number subject estimate study depend number group enrol . The start dose 5 mg give orally tablet formulation .</brief_summary>
	<brief_title>Clinical Study Evaluate Maximum Tolerated Dose BAY87-2243 Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>Male female subject age &gt; /= 18 year Subjects advance , histologically cytologically confirm solid tumor , refractory standard therapy , standard therapy available , subject must actively refuse treatment would regard standard , / judgement investigator , experimental treatment clinically ethically acceptable Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy least 3 month Adequate bone marrow , liver , renal function History cardiac disease include congestive heart failure &gt; NYHA ( New York Heart Association ) II , unstable angina ( anginal symptom rest ) , newonset angina ( within past 3 month ) myocardial infarction within past 6 month cardiac arrhythmia require antiarrhythmic therapy except betablockers digoxin History ischemic cardiovascular disease Family history long QT syndrome Persistent hypokalemia &lt; 3.5 mmol/L History cerebral ischemia include transient ischemic attack ( TIA ) , prolong reversible ischemic neurologic deficit ( PRIND ) , ischemic stroke within past 6 month Known alcohol abuse Moderate severe hepatic impairment , i.e . ChildPugh class B C Diabetes mellitus treat oral antidiabetic insulin History human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Active clinically serious infection CTCAE &gt; Grade 2 ( Common Terminology Criteria Adverse Events v4.02 ) Symptomatic metastatic brain meningeal tumor unless subject &gt; 6 month definitive therapy , evidence tumor growth image study within 4 week prior study entry , clinically stable respect tumor time study entry . Unresolved specific chronic toxicity CTCAE &gt; Grade 2 Subjects may receive potent inducer CYP3A4 , phenytoin , carbamazepine , rifampicin , oral clearance ondansetron may increase ondansetron plasma concentration may decrease due antiemetic regimen Concomitant medication metformin Concomitant medication drug know prolong QT interval Relevant pathological change ECG second thirddegree AV block , prolongation QRS complex 120 m QT / QTcinterval 450 m men woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Hypoxia inducible factor 1 alpha</keyword>
	<keyword>Neoplasms</keyword>
</DOC>